ImmunityBio, Inc.
Every calculator, already run for IBRX
Open the full toolkit →You have the numbers on IBRX. Get the argument.
A written report on which of these readings actually decide the outcome for ImmunityBio, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
4 analysts covering IBRXAnalyst Price Target Disagreement for ImmunityBio, Inc.
Wall Street's bull case implies +86% from the current price; the bear case implies +49%. A 37% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for IBRX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for…
IBRX — frequently asked
Is IBRX a buy right now?
Wall Street's consensus rating on ImmunityBio, Inc. is none across 4 analysts, with a mean price target of $12.75 (+58% vs. the current $8.08). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is IBRX's next earnings date?
ImmunityBio, Inc. is next scheduled to report earnings around Nov 3, 2026. A full IBRX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for ImmunityBio, Inc.?
Analysts covering ImmunityBio, Inc. (IBRX) range from a bear-case target of $12.00 to a bull-case high of $15.00, with a mean consensus target of $12.75 across 4 analysts. The spread of $3.00 (37% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare ImmunityBio, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For ImmunityBio, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full IBRX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on ImmunityBio, Inc., in minutes. 3 free reports included with every account — no credit card required.